A. Deadlines

Application due: Tuesday July 31, 2018 (by 4:00pm Central)
Earliest possible start: September 1, 2018

B. Purpose

The purpose of the Pancreatic Cancer SPORE Developmental Research Award for Disparities Research is to support new research projects in pancreas cancer prevention, treatment or survivorship that seek to reduce the disproportionate burden of pancreatic cancer among certain populations. This mechanism is specifically allocated for DRPs focused on understanding or reducing racial, socioeconomic, or geographic disparities in pancreatic cancer. The allocated funds will support highly-focused projects intended to collect preliminary data sufficient to support an application for a peer-reviewed research grant or future incorporation as full Pancreatic SPORE projects.

Epidemiology and cancer prevention/control related studies will be highly considered, along with basic science, translational and clinical research studies. Priority will be given, but not limited to, proposals that will lead to larger, funded projects that improve pancreatic cancer outcomes across the lifecourse. All proposals must describe the disparity to be addressed and how their project will address the reduction or elimination of the disparity.

C. Eligibility

Applicant Eligibility:

This RFA is open to investigators affiliated with Washington University and Siteman Cancer Center.

All faculty members (instructor level or higher) are eligible.

Senior post-doctoral fellows who have a written commitment from their department chair indicating promotion to Instructor or Assistant Professor by the time of the award will be eligible.

Preference will be given to junior faculty or established investigators with a new translational pancreatic cancer research focus.

Applications from underrepresented minority investigators are strongly encouraged.

Priority will be given to investigators who have collaborators from other SPORE programs at other institutions.

Specific RFA Requirements:

Each application must be related to pancreatic cancers.

Each application must include use of at least one SCC shared resource or Pancreas SPORE Cores. For more information on SCC cores, link to https://siteman.wustl.edu/research/shared-resources-cores
**D. Amount**

One award will be funded at a maximum of $35,000 for one year. Funded projects that demonstrate substantial and promising progress can apply for an additional year of competitive funding in the future. Detailed budgets and justifications must be submitted and will be administratively reviewed. A start date by July 1, 2018 is expected. The budget should be prepared with your departmental administrator.

**E. Submission Guidelines**

*These are internal awards and are NOT submitted through the Office of Sponsored Research Services.*

**Full Application:** Submit your application as a single PDF to hornj@wustl.edu by the deadline, **Tuesday July 31, 2018, 4:00 pm (Central).** Late submissions will not be accepted.

**Formatting:**

- Use Arial 11 point font for all text and ½” margins.
- Type your name (last name, first name) in the header of each page.
- Page numbers should be in the bottom center of the footer of each page and should continue throughout the full application package. (For example, page numbers should not restart for individual sections, such as biosketches.)
- Follow NIH formatting and PHS 398 forms unless otherwise indicated. Forms can be found at [http://grants.nih.gov/grants/funding/phs398/phs398.html](http://grants.nih.gov/grants/funding/phs398/phs398.html)

**Required Documents:**

1) **Face Page:** Use form page that is provided. A copy is at the end of this packet, and a stand-alone document is available on the website.

2) **Additional Information Page:** Human Research Studies: All new cancer-related research involving human subjects (HS) requires approval by the Human Studies Committee (HSC) and must be first reviewed and approved by the Siteman Cancer Center Protocol Review and Monitoring Committee (PRMC). Funds will not be released prior to PRMC and HSC approval. Use a continuation form page to describe your HS and whether your HRPO application is pending or approved. If approved, the approval should be included in the Appendix of the application.

3) **Budget & Justification:** Budgets will receive additional independent review by the Development Research Committee. Expenditures should be appropriate and carefully justified. The Development Research Committee reserves the right to reduce award amounts. Use NIH Form Pages 4 and 5 for the budget. Use NIH Continuation Form pages as needed. When completing the budget page, please refer to the list of expenditures allowed and not allowed:

**Facilities and Administrative (F/A)/Indirect Costs:** Do not include indirect costs at time of submission. If appropriate, based on the funding source, indirect costs will be added post-award.

**Expenditures Allowed**

- Salary support for investigators and other relevant faculty collaborators or staff (NOTE: The NIH salary cap applies to these awards)
- Research supplies and animal maintenance (including animal per diem charges)
- Per diem charges for patients if part of a clinical study not reimbursable by standard payment terms
- Technical assistance
- Domestic travel when necessary to carry out the proposed research program
• Publication costs, including reprints, study instruments, surveys, etc.
• Registration fees at scientific meetings where the results of the research supported by this award are being presented
• Costs of computer time
• Special fees (pathology, photography, etc.)
• Stipends for graduate students and postdoctoral assistants if their role is to promote and sustain the project presented by the faculty member (please justify in budget justification)
• Non-office equipment costing less than $5,000. Special justification is necessary for items exceeding this amount, and permission must be obtained from the Developmental Research Committee for the purchase of such equipment.

Expenditures NOT Allowed
• Secretarial/administrative personnel salary support
• Office equipment and supplies
• Computer/equipment maintenance fees
• Tuition
• Foreign travel
• Purchasing and binding of periodicals and books
• Dues and membership fees in scientific societies
• Honoraria and travel expenses for visiting lecturers
• Recruiting and relocation expenses
• Office and laboratory space
• Rental of office or laboratory space
• Non-medical or personnel services to patients
• Construction or building maintenance
• Indirect institutional costs (Do not include indirect funds on your budget.)

4) NIH Biosketch: Biosketches are required for all key personnel. Use current NIH format and guidelines, and include PMCID numbers on publications. [http://grants.nih.gov/grants/forms/biosketch.htm](http://grants.nih.gov/grants/forms/biosketch.htm)

5) Other Support: Other Support documents are required for all key personnel. Use the NIH Other Support format. [http://grants.nih.gov/grants/funding/2590/2590.htm](http://grants.nih.gov/grants/funding/2590/2590.htm)

6) Research Plan (6 page maximum. All tables and figures are included in the 6 page limit). The following headings should be used:

**Specific Aims**: State concisely the hypothesis to be tested and the specific aim(s) to be achieved during the grant period. The aims must be reasonable to achieve during the one-year period of the grant.

**Significance to Pancreatic Cancer Disparity Research**: All proposals must describe the disparity to be addressed and how their project will address the reduction or elimination of the disparity. Please specify if the project is translational or will lead to translational research opportunities. Discuss the use of one or more SCC or Pancreas SPORE core facilities.

**Background and Preliminary Investigations**: Discuss the pertinent research findings that have been described in the scientific literature and how this proposal will add to these results. Also discuss any preliminary data obtained that are relevant to this proposal.

**Experimental Design and Methods**: Concisely present the experimental design and the methods to be used to accomplish the specific aims. Also indicate how the results will be interpreted and how they will lead to future investigations. Well-known methods and standard procedures may be described very briefly or referenced, but novel experimental approaches should be outlined in more detail. Please include a statistical review. For projects that include a clinical trial or the use of human tissue, a plan to ensure minority participation will be required, and the study must be ready for activation within six months of award.
7) **Plans for Subsequent Funding**: Describe plans for future, collaborative applications based on the proposed seed grant. In the review, substantial weight will be given to the intellectual quality and feasibility of these plans along with the extent to which they continue to reflect inter-programmatic collaboration.

8) **Literature Cited**: Include PMCIDs.

9) **Appendix**
   - Copies of submitted or approved regulatory forms for PRMC, HSC, Animal Studies Committee, Radiation Safety, etc.). These documents will be required before funds are released.
   - Letters of Support, if applicable. Applicants who are junior faculty members (Instructor or Assistant Professor) must include a letter of support from their Department or Division Chair. If the project requires a sponsor, consultant or collaborator, this individual should write a letter of support for the application, including an explanation of how any overlap in effort will be reconciled if the project is funded.

If you have questions, please contact Jody Horn, hornj@wustl.edu, 314-273-6055.

**F. Terms of the Award**

- Up to $35,000 will be provided in the funding period of September 1, 2018 through June 30, 2019. It is expected that the grantee will completely utilize the full amount of funding during the funding period.
  - No-cost extensions and carryover are generally not allowed, but will be considered on a case-by-case basis by the Developmental Research Committee. Requests must be made 90 days prior to the end of the funding period.
  - All unspent funds at the end of the grant period (unless you have requested and been granted a no-cost extension) will be returned.

- IRB & IACUC approvals are not required at the time of submission. However, all awards must have appropriate institutional regulatory approvals (SCC Protocol Review and Monitoring Committee, Human Studies Committee, Animal Studies, Radiation Safety) before funds will be transferred.

- Grantees will be required to submit to the Pancreatic Cancer SPORE Developmental Research Committee a brief progress report describing the results of their work, as well as related publications and funding. An annual progress report is required to be submitted by April 1, 2019. Acceptance of funds implies a firm commitment to provide this progress report to the committee in a timely manner.

- Awardees will present their findings annually at a SPORE steering committee meeting.

- Any publication resulting from research supported by the Pancreatic Cancer SPORE must acknowledge this support. Publications are subject to the NIH Public Access Policy and will need to be submitted to PubMed Central and receive a PMCID. Awardees are required to inform the Pancreatic Cancer SPORE by contacting Jody Horn (314-273-6055, hornj@wustl.edu) if the research supported by a Pancreatic Cancer SPORE award leads to further extramural research funding or publications.
  - Please use this acknowledgement in your publications and presentations:
    
    **This research is supported by grant P50CA196510 from the National Cancer Institute; Washington University in St. Louis School of Medicine, the Department of Surgery, and Siteman Cancer Center; University of Rochester, University of North Carolina at Chapel Hill (Lineberger Comprehensive Cancer Center), and Johns Hopkins Medicine (The Sidney Kimmel Comprehensive Cancer Center).**
G. Review Process

All applications will be evaluated in a rigorous review by at least two unbiased reviewers, a biostatistician from the Biostatistics Core, and an ad hoc patient advocate and scored for scientific merit and translational impact according to the following criteria:

- The overall quality of the science proposed
- Novelty of the proposal
- The likelihood that it will result in translational research
- The degree to which the project represents a new resource for studying pancreas cancer
- The possibility that the project could lead to a full SPORE project or an independently funded project
- The contribution of the project to the overall goals of the Pancreas SPORE
- The use of shared SPORE and SCC resources
- For projects that include a clinical trial or the use of human tissue, a plan to ensure minority participation will be required and the study must be ready for activation within six months of award.

Contacts

Administrative Contact: Jody Horn; hornj@wustl.edu; 314-273-6055
DRP Director: Lee Ratner, MD, PhD; iratner@wustl.edu
Associate DRP Director: David C. Linehan, MD; David_Linehan@urmc.rochester.edu
SPORE Director: William G. Hawkins, MD; hawkinsw@wustl.edu

The DRP is supported by grant P50CA196510 from the National Cancer Institute; Washington University in St. Louis School of Medicine, the Department of Surgery, and Siteman Cancer Center; University of Rochester, University of North Carolina at Chapel Hill (Lineberger Comprehensive Cancer Center), and Johns Hopkins Medicine (The Sidney Kimmel Comprehensive Cancer Center).
Title of Project (no more than 81 characters):

| Project Start Date: | 7/1/2018 | Project End Date: | 6/30/2019 |

**Principal Investigator (PI)**

| Name: (Last, First, Middle): | | Degree(s): | |
| Title: | Mailing Address: | |

**Applicant Organization:**

| Department: | Division: | E-mail Address: | Phone Number: |

**Grant Administrator**

| Contact Name: | Phone Number: | E-mail Address: |

**HUMAN SUBJECTS RESEARCH**

| IRB APPROVAL | IRB PROTOCOL NUMBER (IF APPROVED) | APPROVAL DATE (IF APPROVED) |
| Clinical Trial | | |
| No | No | Yes |

| PENDING | DATE ANTICIPATED (IF PENDING) | FWA NUMBER |
| No | Yes |

**VERTEBRATE ANIMALS**

| IRB APPROVAL | IACUC PROTOCOL NUMBER (IF APPROVED) | APPROVAL DATE (IF APPROVED) |
| No | Yes |

| PENDING | DATE ANTICIPATED (IF PENDING) | AWA NUMBER |
| No | Yes |

Please check all that apply:

- Junior faculty as of 7/1/2018 (Instructor or Assistant Professor without R01 or equivalent grant)
- Established faculty with a new translational pancreatic cancer research focus
- Under-represented minority investigator
- Project includes collaborators from other SPORE programs at other institutions

List Co-Investigators/Collaborators expected to participate on project.

<table>
<thead>
<tr>
<th>Name</th>
<th>Prime Institution</th>
<th>Department/Division</th>
</tr>
</thead>
</table>

SIGNATURE OF PRINCIPAL INVESTIGATOR

Electronic signatures are acceptable.